Patrick Sharma

Cooley advised Vision Government Solutions, a portfolio company of Rubicon Technology Partners and a leader in the appraisal, computer-assisted mass appraisal and property tax industry, on its majority recapitalization with Great Hill Partners.

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised the Boston Celtics and the Grousbeck family – the majority stakeholders of Boston Basketball Partners, which owns the American professional basketball team – in connection with their agreement to sell the Celtics to an investor group led by William Chisholm.

Cooley advised Tenable Holdings, the exposure management company, on its definitive agreement to acquire Eureka Security, a provider of data security posture management (DSPM) for cloud environments.

Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.